45
total announcements
SENORES.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹5,773 Cr
P/E (TTM)
44.2
P/E (Forward)
25.3
EPS (TTM)
₹28.39
52W Low
₹706.00
52W High
₹1,599.00
Dividend Yield
0.00%
Price / Book
5.3
Debt / Equity
35.5
Revenue (TTM)
₹680 Cr
Gross Margin
62.37%
Operating Margin
24.32%
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange about the completion of dispatch of Notice of Postal Ballot, intimation of e-voting and other related information, as per Regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot for seeking approval of the shareholders for re-appointment of Mr. Swapnil Jatinbhai Shah as the Managing Director and Mr. Chetan Bipinchandra Shah as the Whole Time Director of the Company.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding the re-appointment of Mr. Swapnil Jatinbhai Shah as the Managing Director and Mr. Chetan Bipinchandra Shah as the Whole Time Director of the company, both liable to retire by rotation for a period of three consecutive years.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding the re-appointment of Mr. Chetan Bipinchandra Shah as the Whole Time Director of the Company, liable to retire by rotation for a period of three consecutive years w.e.f. November 10, 2026, subject to the approval of shareholders to be obtained through postal ballot process.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their Meeting held today i.e., Tuesday, October 13, 2026, approved the re-appointment of Mr. Swapnil Jatinbhai Shah as the Managing Director of the Company and Mr. Chetan Bipinchandra Shah as the Whole Time Director of the Company, both for a period of three consecutive years subject to the approval of shareholders.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has submitted a certificate under Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018, detailing the reconciliation of its share capital audit report for the quarter ended September 30, 2026.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding Scrutinizer Report and Voting results of 09th Annual General Meeting.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026. The meeting was held through Video Conferencing and was attended by 49 members, including corporate bodies through their representative. The proceedings of the AGM are enclosed as Annexure A and will be made available on the company's website.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has clarified that there is no undisclosed or price-sensitive information and will continue to inform the exchanges of all material events as required under SEBI (LODR) Regulations 2015.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange about the successful completion of a USFDA inspection at its subsidiary company's manufacturing facility in Vadodara. The inspection was conducted from September 7 to September 11, 2026, and resulted in one minor procedural observation with no GMP-related issues.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication with respect to the 9th Annual General Meeting of the Company.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding Notice of 9th Annual General Meeting to be held on September 25, 2026.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting to be held on September 2, 2026, at Elara Capital Group in Mumbai.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding a copy of newspaper publication for the pre dispatch of Annual Report for the forthcoming Annual General Meeting of the Company.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has announced the outcome of its Board Meeting held on August 26, 2026, where it approved several key decisions, including the appointment of a Company Secretary and Compliance Officer, a Non-Executive Additional Director, and authorized officers to determine materiality of events or information. The company also approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 and proposed the incorporation of a Subsidiary Company in Canada to support its business and strategic objectives in the Canadian and other international markets.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding the outcome of its Board Meeting held on August 26, 2026, where it approved the appointment of a Company Secretary and Compliance Officer, a Non-Executive Additional Director, and authorized officers to determine materiality of events or information and make disclosures to stock exchanges. The Board also approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 and the incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary Company in Canada.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 26, 2026, where the Board approved the appointment of Company Secretary and Compliance Officer, Non-Executive Additional Director, authorized officers for determining materiality of events, and approved the adoption of Employee Stock Option Scheme 2026 and proposed incorporation of Wholly Owned Subsidiary in Mexico and Subsidiary Company in Canada.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding the appointment of Mrs. Shilpa Sharma as Company Secretary & Compliance Officer, Mr. Viranchi Arvindbhai Shah as Non-Executive Additional Director, and the approval of Senores Pharmaceuticals Employee Stock Option Scheme 2026. The company also proposed the incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary Company in Canada.